spacer
home > pmps > autumn 2019 > the challenges in starting 4.0 projects
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Challenges in Starting 4.0 Projects





Pharma 4.0 is now a prevailing reality that has many advantages such as in-line and in-time control over manufacturing operations and faster decision-making (1-2). Nevertheless, the dangers of investing in wrong ways exist; investing in technologies that suit the company needs is strongly advised, that is, the ones that help provide the most efficient solutions to the problems faced by the company. Peter Guilfoyle writes that “the potential for Pharma 4.0 is so huge, and so wide, that a lot of pharmaceutical companies rushing to adopt the technology haven’t first paused to figure out the root goals that they are trying to achieve, and what main problems they are trying to solve”.

Launching a digitisation project indeed requires an approach to be chosen according to the expected benefits. However, all biopharma companies have at least two objectives in common: reducing operational supply chain costs and scaling down the data recording administrative burden. Investing in Pharma 4.0 technologies should aim to achieve these goals.
 

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Denis Decubber has a degree in Chemical Engineering. His professional experience covers quality management systems and especially GMP/GCP/GTP systems, more specifically those dedicated to cell and gene therapy operations. This certainly provides added value when it comes to understanding customers’ business processes: manufacturing and quality control processes, clinical study processes, support processes related to premises, equipment and subcontractors, and improvement processes (for example, risks, deviations, and out-of-specification issues). He is Chairman of SalamanderU’s board of directors.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement